Physician profile
Gerald A Ravitz
NPI 1174591515
$1,120.05
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $537 · 2021: $375.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $396.36 | 2019-2021 | |
| Astellas Pharma US INC | $371.17 | 2019-2021 | |
| Abbvie INC. | $130.39 | 2019-2021 | |
| Pfizer INC. | $105.43 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $49.89 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.75 | 2021 | |
| Foundation Medicine, INC. | $13.15 | 2020 | |
| Merck Sharp & Dohme LLC | $12.87 | 2020 | |
| Urovant Sciences INC | $11.58 | 2021 | |
| Travere Therapeutics, INC. | $11.46 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$986.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Ravitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.